James Ingle

Has grant

Mayo Clinic Rochester
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Pharmacogenomics of Endocrine Therapy

Open Date: 2019-10-01

Close Date: 2020-09-30

Grant: Close

Precision Breast Cancer Prevention: Mechanisms of regulation of BRCA1 by ZNF423 and CTSO in a SNP dependent fashion upon estrogen or SERM treatment

Open Date: 2014-10-01

Close Date: 2015-09-30

Grant: Close

Analysis of the functions of estrogen receptor beta and its variants in human breast cancer.

Open Date: 2013-07-26

Close Date: 2016-02-09

Grant: Close

Analysis of the functions of estrogen receptor beta (Erß) and its variants in human breast cancer

Open Date: 2012-07-24

Close Date: 2018-02-22

Grant: Close

Analysis of the functions of estrogen receptor beta (Erß) in human breast cancer

Open Date: 2011-07-29

Close Date: 2018-02-22

Articles (13)

Year:

2026

Year:

2026

Year:

2025

PURPOSE Adjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%) is unclear. METHODS Using the National Cancer Database, we studied patients with high-risk stage I to III, ER-low BC (defined as immunohistochemistry 1%-10%) who received (neo)adjuvant chemotherapy and did or did not initiate ET. OS was analyzed with ET initiation as a time-dependent covariate using Cox proportional hazards regression. RESULTS Of 10,362 patients with stage I to III ER-low BC, 7,018 received chemotherapy and met inclusion criteria. ET omission was 42% at 12 months and more common in patients with tumors that were progesterone receptor–negative, human epidermal growth factor receptor 2–negative, higher-grade (grade 2/3) and higher Ki-67 (≥20%; all P < .001) and those who received neoadjuvant chemotherapy (NAC; P < .001). With a median follow-up of 3 years, 586 deaths were observed. In a multivariable analysis, ET omission was associated with a higher risk of death (hazard ratio [HR], 1.23 [95% CI, 1.04 to 1.46]; P = .02), with a greater impact in those with higher ER levels: ER 1%-5% (HR, 1.15 [95% CI, 0.91 to 1.45]; P = .24) versus ER 6%-10% (HR, 1.42 [95% CI, 1.00 to 2.02]; P = .048). Among patients treated with NAC (n = 4,377, 62%), ET omission was associated with worse OS in those with residual disease (RD; HR, 1.26 [95% CI, 1.00 to 1.57]; P = .046) but not in those who achieved a pathologic complete response (HR, 1.06 [95% CI, 0.62 to 1.80]; P = .84). CONCLUSION In ER-low, early-stage BC, ET omission is associated with significantly worse OS, especially in patients with RD after NAC and those with higher (6%-10%) ER levels. Until prospective data are available, patients with ER-low BC should be counseled regarding the potential benefit of ET.

Year:

2025

Year:

2025

Year:

2025

Supplementary Figure 2 displays the relationship between the week 8 CM level and the change in CM level (Week 8 – baseline). Figure S4B and C use box plots to display the relationship between disease status at first restaging and week 8 CM level or change in CM level (Week 8 – baseline).

Year:

2025

Supplementary figure 5 displays time updated ROC curves for (A) CM level at week 8, (B) Change in CM level (Week8 – Week4) and (C) the Combination of week 8 CM level and Change in CM level (Week 8-Week 4) using linear discriminant analysis.

Year:

2025

Purpose: We previously demonstrated that high levels of circulating methylated DNA are associated with subsequent disease progression in women with metastatic breast cancer (MBC). In this study, we evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay using the GeneXpert cartridge system for early assessment of disease progression in MBC. Experimental Design: The 9-marker LBx-BCM prototype assay was evaluated in TBCRC 005, a prospective biomarker study, using plasma collected at baseline, week 4, and week 8 from 144 patients with MBC. Results: At week 4, patients with MBC with high cumulative methylation (CM) had a significantly shorter median PFS (2.88 months vs. 6.60 months, P = 0.001) and OS (14.52 months vs. 22.44 months, P = 0.005) compared with those with low CM. In a multivariable model, high versus low CM was also associated with shorter PFS (HR, 1.90; 95% CI, 1.20–3.01; P = 0.006). Change in CM from baseline to week 4 (OR, 4.60; 95% CI, 1.77–11.93; P = 0.002) and high levels of CM at week 4 (OR, 2.78; 95% CI, 1.29–5.99; P = 0.009) were associated with progressive disease at the time of first restaging. A robust risk model based on week 4 circulating CM levels was developed to predict disease progression as early as 3 months after initiating a new treatment. Conclusions: The automated LBx-BCM prototype assay is a promising clinical tool for detecting disease progression a month after initiating treatment in women with MBC undergoing routine care. The next step is to validate its clinical utility for specific treatments.

Year:

2025

PURPOSE ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity with breast cancer outcomes. METHODS MA.27 (ClinicalTrials.gov identifier: NCT00066573 ) was a phase III adjuvant trial of exemestane versus anastrozole in postmenopausal women with early-stage breast cancer. Immunochemistry ER and PgR HSCORE and % positivity (%+) were centrally assessed by machine image quantitation and statistically standardized to mean 0 and standard deviation (SD) 1 after Box-Cox variance stabilization transformations of square for ER; for PgR, (1) natural logarithm (0.1 added to 0 HSCOREs and 0%+) and (2) square root. Our primary end point was MA.27 distant disease-free survival (DDFS) at a median 4.1-year follow-up, and secondary end point was event-free survival (EFS). Univariate survival with cut points at SDs about a mean of 0 (≤–1; (–1, 0]; (0, 1]; >1) was described with Kaplan-Meier plots and examined with Wilcoxon (Peto-Prentice) test statistic. Adjusted Cox multivariable regressions had two-sided Wald tests and nominal significance P < .05. RESULTS Of 7,576 women accrued, 3,048 women's tumors had machine-quantitated image analysis results: 2,900 (95%) for ER, 2,726 (89%) for PgR, and 2,582 (85% of 3,048) with both ER and PgR. Higher statistically standardized ER and PgR HSCORE and %+ were associated with better univariate DDFS and EFS ( P < .001). In multivariable assessments, ER HSCORE and %+ were not significantly associated ( P = .52-.88) with DDFS in models with PgR, whereas higher PgR HSCORE and %+ were significantly associated with better DDFS ( P = .001) in models with ER. CONCLUSION Adjunctive statistical standardization differentiated quantitated levels of ER and PgR. Patients with higher ER- and PgR-standardized units had superior DDFS compared with those with HSCOREs and %+ ≤–1.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (19)

Lisa Anne Carey

Deputy Director for Clinical Science

University of North Carolina at Chapel Hill

UNITED STATES
View details

Zeruesenay Desta

Professor of Medicine

Indiana University

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Matthew J. Ellis

Director

Baylor College of Medicine

UNITED STATES
View details

Nancy Lin

Associate Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Rita Nanda

Associate Professor of Medicine; Director Breast Oncology

University of Chicago

UNITED STATES
View details

Matthew Goetz

Professor of Oncology and Pharmacology

Mayo Clinic

UNITED STATES
View details

Michael Bates

-

UNITED STATES
View details

Karthik Giridhar

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Vered Stearns

Weill Cornell Medicine

UNITED STATES
View details

Ravinder Singh

Professor

Mayo Clinic

UNITED STATES
View details

Antonio Wolff

Professor of Oncology

Johns Hopkins University

UNITED STATES
View details

Kala Visvanathan

Professor

Johns Hopkins University

UNITED STATES
View details

Saranya Chumsri

Professor of Oncology

Mayo Clinic Florida

UNITED STATES
View details

Saraswati Sukumar

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Kathryn Ruddy

Professor

Mayo Clinic

UNITED STATES
View details

Arnab Ghosh

Flinders University

AUSTRALIA
View details

Timothy J Whelan

-

CANADA
View details

Kostandinos Sideras

Assistant Professor

Mayo Clinic

UNITED STATES
View details